Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigator-and-subject Blind, Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Repeat Doses Of Pf-06648671 In Healthy Adult Subjects And Healthy Elderly Subjects

NCT02440100 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02440100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02440100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigator-and-subject Blind, Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Repeat Doses Of Pf-06648671 In Healthy Adult Subjects And Healthy Elderly Subjects
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2015
Completion date
October 31, 2016
Enrollment
92 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adult subjects and healthy elderly subjects